One of the challenges manufacturers face is ensuring sufficient evidence to support not only product approval, but also reimbursement and market adoption. This is particularly relevant for early stage biotech companies that tend to focus on regulatory submission and not on how the product will be reimbursed and ultimately adopted.

Michael Abrams and fellow experts from Takeda Ventures, Mallinckrodt and Chiesi held a dynamic conversation on An Investor’s Perspective on Value of New Biotherapeutics.  During the session, they discussed maximizing the value of products and factoring evolving evidence requirements into investment decisions.

Speakers included:

• Dr. Karen Hong, Senior Investment Director, Takeda Ventures
• Joshua Schafer, General Manager, International and Vice President, Business Development and Licensing, Mallinckrodt Pharmaceuticals
• Joshua Franklin, Senior Vice President, Marketing and Corporate Development, Chiesi Group

The panel was held on Thursday, June 7, 2018.  For more information about this conference, please visit bio.org.